Genetic polymorphisms of CYP2D6 oxidation in patients with inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 55, Issue 4, 2010, Pages 1037-1043

  Trzcinski, R ^a   Skretkowicz, J ^a   Dziki, A ^a   Rychlik Sych, M ^a   Baranska, M ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

CYP2D6; Genetic polymorphism; Inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYTOCHROME P450 2D6; DNA; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DNA EXTRACTION; ENTERITIS; ENZYME METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMICOLECTOMY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCTOCOLECTOMY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SIGMOIDECTOMY; ULCERATIVE COLITIS; VOLUNTEER; COLORECTAL TUMOR; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE DETECTION; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION;

ADULT; AGED; ALLELES; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; CYTOCHROME P-450 CYP2D6; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; YOUNG ADULT;

EID: 77950347698     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0816-2     Document Type: Article

References (58)

1. A Bołdys M Hartleb H Bołdys M Kajor K Rudzki A Nowak 2005 Demographic characteristics of patients with inflammatory bowel disease-twenty years later Gastroenterol Pol 12 1 9 12
2. YR Parc E Radice RR Dozois 1999 Surgery for ulcerative colitis: Historical perspective. A century of surgical innovations and refinements Dis Colon Rectum 42 299 306 10.1007/BF02236342 10.1007/BF02236342 1:STN:280:DyaK1M3jvValsQ%3D%3D 10223747
3. A Dziki R Trzciński A Sygut 2004 The role of surgical treatment in inflammatory bowel disease Pediatria Współczesna. Gastroenterologia. Hepatol Zywienie Dziecka 6 4 455 459
4. R Trzciński A Sygut A Dziki 2005 Surgical treatment of Crohn's disease Terapia XIII 6 50 52
5. A Sygut R Trzciński A Skowroński A Dziki 2005 Surgical treatment of ulcerative colitis Terapia XIII 6 53 56
6. RR Cima JH Pemberton 2005 Medical and surgical management of chronic ulcerative colitis Arch Surg 140 300 310 10.1001/archsurg.140.3.300 10.1001/archsurg.140.3.300 15781797 (Pubitemid 41001826)
7. C Fiocchi 2002 Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy Minerva Gastroenterol Dietol 48 3 215 226 1:STN:280:DC%2BD287gtl2nsA%3D%3D 16491045
8. JR Monson 2007 Colorectal website review. Inflammatory bowel disease Dis Colon Rectum 50 1094 1098 10.1007/s10350-006-0795-8 10.1007/s10350-006-0795-8
9. H Yang JI Rotter 2000 The genetic background of inflammatory bowel disease Hepatogastroenterology 47 31 5 14 1:CAS:528:DC%2BD3cXhtlCrtbg%3D 10690581
10. LA Garcia Rodriguez A Gonzalez-Perez S Johansson 2005 Risk factors for inflammatory bowel disease in the general population Aliment Pharmacol Ther 22 4 309 315 10.1111/j.1365-2036.2005.02564.x 10.1111/j.1365-2036.2005.02564.x 1:STN:280:DC%2BD2MvjtFelsw%3D%3D 16097997 (Pubitemid 41207460)
11. Okabe N. The pathogenesis of Crohn's disease. Digestion. 2001;63(Suppl):52-59. doi: 10.1159/000051912. (Pubitemid 32098442)
12. J Pravda 2005 Radical induction theory of ulcerative colitis World J Gastroenterol 11 16 2371 2384 1:CAS:528:DC%2BD2MXltVWisLs%3D 15832404
13. R Trzciński M Bryś W Krajewska A Kulig A Dziki 2004 ErbB-1 expression in experimental model of inflammatory bowel disease in rats Acta Chir Iugosl LI 85 89
14. G Bamias C Martin M Martini 2003 Expression, localization and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease J Immunol 171 9 4868 4874 1:CAS:528:DC%2BD3sXot1Cnu7c%3D 14568967
15. DK Bonen JH Cho 2003 The genetics of inflammatory bowel disease Gastroenterology 124 2 521 536 10.1053/gast.2003.50045 10.1053/gast.2003.50045 1:CAS:528:DC%2BD3sXhsFOgs78%3D 12557156 (Pubitemid 36169267)
16. W Cao MD Vrees MT Kirber 2004 Hydrogen peroxide contributes to motor dysfunction in ulcerative colitis Am J Physiol Gastrointest Liver Psychol 286 5 G833 G843 10.1152/ajpgi.00414.2003 10.1152/ajpgi.00414.2003 1:CAS:528: DC%2BD2cXkt1els7o%3D (Pubitemid 38506816)
17. D Franchimont S Vermeire H El Housni 2004 Deficient host-bacteria interactions in inflammatory bowel disease. The toll-like receptor (TLR)-4Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis Gut 53 7 987 992 10.1136/gut.2003.030205 10.1136/gut.2003.030205 1:CAS:528:DC%2BD2cXlvFemtrY%3D 15194649 (Pubitemid 38824157)
18. E Furrie S Macfariane JH Cummings 2004 Systematic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response Gut 53 1 91 98 10.1136/gut.53.1.91 10.1136/gut.53.1.91 1:CAS:528:DC%2BD2cXptlKqtA%3D%3D 14684582 (Pubitemid 38083016)
19. J Hampe S Schreiber SH Shaw 1999 A genomewide analysis provides evidence for novel linkage in inflammatory bowel disease in a large European cohort Am J Hum Genet 64 3 808 816 10.1086/302294 10.1086/302294 1:CAS:528: DyaK1MXitFChtL8%3D 10053016 (Pubitemid 30460424)
20. CG Mathew CM Lewis 2004 Genetics of inflammatory bowel disease: Progress and prospects Hum Mol Genet 13 R161 R168 10.1093/hmg/ddh079 10.1093/hmg/ddh079 1:CAS:528:DC%2BD2cXivFCku7o%3D 14764625
21. T Onkusa T Nomura N Sato 2004 The role of bacterial infection in the pathogenesis of inflammatory bowel disease Intern Med 43 7 534 539 10.2169/internalmedicine.43.534 10.2169/internalmedicine.43.534 (Pubitemid 39206689)
22. M Schultz A Timmer HH Herfarth RB Sartor 2004 Lactobacillus GG in inducing and maintaining remission of Crohn's disease BMC Gastroenterol 4 1 5 10.1186/1471-230X-4-5 10.1186/1471-230X-4-5 15113451 (Pubitemid 38671545)
23. V Seagroatt MJ Goldacre 2003 Crohn's disease, ulcerative colitis, and measles vaccine in an English population, 1979-1998 J Epidemiol Community Health 57 11 883 887 10.1136/jech.57.11.883 10.1136/jech.57.11.883 1:STN:280:DC%2BD3srit1emtw%3D%3D 14600114 (Pubitemid 37410005)
24. AJ Stagg AL Hart SC Knight 2003 The dendritic cell: Its role in intestinal inflammation and relationship with gut bacteria Gut 52 10 1522 1529 10.1136/gut.52.10.1522 10.1136/gut.52.10.1522 1:CAS:528:DC%2BD3sXotl2ks74%3D 12970149 (Pubitemid 37176736)
25. BA Hendrickson R Gokhale JH Cho 2002 Clinical aspects and pathophysiology of inflammatory bowel disease Clin Microbiol Rev 15 1 79 94 10.1128/CMR.15.1.79-94.2002 10.1128/CMR.15.1.79-94.2002 11781268 (Pubitemid 34052583)
26. V Konda D Huo G Hermes M Liu R Patel DT Rubin 2006 Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis 12 6 497 502 10.1097/00054725-200606000-00009 10.1097/00054725-200606000-00009 16775494
27. J Glas K Martin G Brunnler R Kopp C Folwaczny EH Weiss ED Albert 2001 MICA, MICB and C1-4-1 polymorphism in Crohn's disease and ulcerative colitis Tissue Antigens 58 243 249 10.1034/j.1399-0039.2001.580404.x 10.1034/j.1399-0039.2001.580404.x 1:CAS:528:DC%2BD38XltVemtg%3D%3D 11782275 (Pubitemid 34015427)
28. LE Oostenbrug HM van Dullemen GJ te Meerman PL Jansen 2003 IBD and genetics: New developments Scand J Gastroenterol Suppl 239 63 68 10.1080/00855920310002717 10.1080/00855920310002717 14743885
29. RJ Farrell MA Peppercorn 2002 Ulcerative colitis Lancet 359 331 340 10.1016/S0140-6736(02)07499-8 10.1016/S0140-6736(02)07499-8 11830216 (Pubitemid 34119301)
30. E Louis J Belaiche 2000 Genetics of Crohn's disease behaviour Acta Gastroenterol Belg 63 4 377 379 1:STN:280:DC%2BD3M7psFKrsA%3D%3D 11233521
31. S Bernard KA Neville AT Nguyen DA Flockhart 2006 Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications Oncologist 11 126 135 10.1634/theoncologist.11-2-126 10.1634/theoncologist.11- 2-126 1:CAS:528:DC%2BD28XhtFKqsbrJ 16476833 (Pubitemid 43261759)
32. M Ingelman-Sunberg 2005 Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J 5 6 13 10.1038/sj.tpj.6500285 10.1038/sj.tpj.6500285 (Pubitemid 40220611)
33. ML Dahl 2002 Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics. Useful aid to prescribing? Clin Pharmacokinet 41 453 470 10.2165/00003088-200241070-00001 10.2165/00003088-200241070-00001 1:CAS:528:DC%2BD38Xmt12mtbs%3D 12083975
34. S Kortunay A Bozkurt L Bathum NE Basci M Calgüneri K Brøsen, et al. 1999 CYP2D6 polymorphism in systemic lupus erythematosus patients Eur J Clin Pharmacol 55 21 25 10.1007/s002280050587 10.1007/s002280050587 1:CAS:528:DyaK1MXhs1Oltbw%3D 10206080 (Pubitemid 29144095)
35. C Rodriguez-Antona M Ingelman-Sundberg 2006 Cytochrome P450 pharmacogenetics and cancer Oncogene 25 1679 1691 10.1038/sj.onc.1209377 10.1038/sj.onc.1209377 1:CAS:528:DC%2BD28XisFyhtbY%3D 16550168
36. CA Smith AC Gough PN Leigh BA Summers AE Harding DM Maraganore, et al. 1992 Debrisoquine hydroxylase gene polymorphisms and susceptibility to Parkinson's disease Lancet 6 1375 1377 10.1016/0140-6736(92)91196-F 10.1016/0140-6736(92)91196-F
37. WM Chambers BF Warren DP Jewell NJ McC Mortensen 2005 Cancer surveillance in ulcerative colitis Br J Surg 92 928 936 10.1002/bjs.5106 10.1002/bjs.5106 1:STN:280:DC%2BD2MzpsFaluw%3D%3D 16034807 (Pubitemid 41160781)
38. SS Mahid DW Colliver NPS Crawford BD Martini MA Doll DW Hein, et al. 2007 Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma BMC Med Genet 8 28 34 10.1186/1471-2350-8-28 10.1186/1471-2350-8-28 17537267 (Pubitemid 47034024)
39. AC von Roon G Reese J Teare V Constantinides AW Darzi PP Tekkis 2007 The risk of cancer in patients with Crohn's disease Dis Colon Rectum 50 839 855 10.1007/s10350-006-0848-z 10.1007/s10350-006-0848-z (Pubitemid 46870441)
40. L Wiederoff TL Vaughan FM Farin MD Gammon H Risch JL Stanford, et al. 2007 GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas Cancer Detect Prev 31 233 236 10.1016/j.cdp.2007.03.004 10.1016/j.cdp.2007.03.004 (Pubitemid 47260667)
41. DW Nebert AL Roe 2001 Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer Sci Total Environ 274 93 102 10.1016/S0048-9697(01)00732-X 10.1016/S0048-9697(01)00732-X 1:CAS:528: DC%2BD3MXks1ejs7w%3D (Pubitemid 32591384)
42. AD Rodrigues TH Rushmore 2002 Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences Curr Drug Metab 3 289 309 10.2174/1389200023337522 10.2174/1389200023337522 1:CAS:528: DC%2BD38Xkslyrs78%3D 12083322 (Pubitemid 34625041)
43. T Fukuda H Maune Y Ikenaga M Naohara K Fukuda J Azuma 2005 Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele Drug Metab Pharmacokinet 20 345 350 10.2133/dmpk.20.345 10.2133/dmpk.20.345 1:CAS:528:DC%2BD2MXhtleksb%2FK 16272752
44. L Gomes MC Lemos I Paiva C Ribeiro M Carvalheiro FJ Regateiro 2005 CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors Acta Med Port 18 339 344 1:CAS:528:DC%2BD28XivFeqt7c%3D 16611538
45. JA Agundez MC Ledesma J Benitez JM Ladero A Rodriguez-Lescure E Diaz-Rubio, et al. 1995 CYP2D6 genes and risk of liver cancer Lancet 345 830 831 10.1016/S0140-6736(95)92965-7 10.1016/S0140-6736(95)92965-7 1:STN:280:DyaK2M3gs1SitQ%3D%3D 7898230
46. RC Sobti K Onsory AI Al-Badran P Kaur M Watanabe A Krishan, et al. 2006 CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population DNA Cell Biol 5 287 294 10.1089/dna.2006.25.287 10.1089/dna.2006.25.287 (Pubitemid 43830442)
47. PG Febbo PW Kantoff E Giovannucci M Brown G Chang CH Hennekens, et al. 1998 Debrisoquine hydroxylase (CYP2D6) and prostate cancer Cancer Epidemiol Biomarkers Prev 7 1075 1078 1:CAS:528:DyaK1MXitFehsg%3D%3D 9865424
48. M Gajecka M Rydzanowicz R Jakula-Sztul M Kujawski W Szyfter K Szyfter 2005 CYP1A1, CYP2D6, CYP2E1, Nat2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma Mutat Res 574 112 123 10.1016/j.mrfmmm.2005.01.027 1:CAS:528:DC%2BD2MXks1eit7Y%3D 15914211 (Pubitemid 40725973)
49. A Hirvonen K Husgafvel-Pursianinen S Anttila A Kariajalainen H Vainio 1997 PCR-based CYP2D6 genotyping for Finnish lung cancer patients Pharmacogenetics 3 19 27 10.1097/00008571-199302000-00002 10.1097/00008571- 199302000-00002
50. JA Agundez 2004 Cytochrome P-450 gene polymorphism and cancer Curr Drug Metab 5 211 224 10.2174/1389200043335621 10.2174/1389200043335621 1:CAS:528:DC%2BD2cXktlKksrk%3D 15180491 (Pubitemid 38735776)
51. RC Sobti AI Al-Badran S Sharma SK Sharma A Krishan H Mohad 2005 Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India Cancer Genet Cytogenet 156 68 73 10.1016/j.cancergencyto.2004.04.001 10.1016/j.cancergencyto.2004.04.001 1:CAS:528:DC%2BD2cXhtVKksLrM 15588859 (Pubitemid 39601062)
52. L Laforest H Wikman S Benhamou ST Saarikoski C Bouchardy A Hirvonen, et al. 2000 CYP2D6 gene polymorphism in Caucasian smokers: Lung cancer susceptibility and phenotype-genotype relationships Eur J Cancer 36 1825 1832 10.1016/S0959-8049(00)00185-4 10.1016/S0959-8049(00)00185-4 1:CAS:528: DC%2BD3cXmtF2jt7s%3D 10974631 (Pubitemid 30639503)
53. C Sachse G Smith MJ Wilkie JH Barret R Waxman F Sulivan, et al. 2002 A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer Carcinogenesis 23 1839 1849 10.1093/carcin/23.11. 1839 10.1093/carcin/23.11.1839 1:CAS:528:DC%2BD38Xps1ehsrs%3D 12419832
54. S Landi F Gemignani V Moreno L Gioia-Patricola A Chabrier E Guino, et al. 2005 A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer Pharmacogenet Genomics 15 535 546 10.1097/01.fpc.0000165904.48994.3d 10.1097/01.fpc.0000165904.48994.3d 1:CAS:528:DC%2BD2MXmtVSnt74%3D 16006997
55. WJ Butler P Ryan IC Roberts-Thomson 2001 Metabolic genotypes and risk for colorectal cancer J Gastroenterol Hepatol 16 631 635 10.1046/j.1440-1746.2001. 02501.x 10.1046/j.1440-1746.2001.02501.x 1:CAS:528:DC%2BD3MXlslSlsLc%3D 11422615 (Pubitemid 34188837)
56. FP Perera T Deliang P Brandt-Rauf RM Santella VA Mooney YH Tu, et al. 2006 Lack of Associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in nested case-control study of lung cancer within the physicians' health study Cancer Epidemiol Biomarkers Prev 15 1417 1419 10.1158/1055-9965.EPI-05-0691 10.1158/1055-9965.EPI-05-0691 1:CAS:528:DC%2BD28XmslSgu7w%3D 16835348 (Pubitemid 44125305)
57. HG Xie RB Kim AJJ Wood CM Stein 2001 Molecular basis of ethnic differences in drug disposition and response Annu Rev Pharmacol Toxicol 1 815 850 10.1146/annurev.pharmtox.41.1.815 10.1146/annurev.pharmtox.41.1.815 (Pubitemid 32385908)
58. P Niewiński K Orzechowska-Józwenko M Hurkacz Z Rzemisławska E Jazwińska-Tarnawska, et al. 2002 CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population Eur J Pharmacol 58 533 535 10.1007/s00228-002-0505-y 10.1007/s00228-002-0505-y (Pubitemid 35439153)